Abstract：
:The effectiveness of current chemotherapeutic approaches for the treatment of solid tumors has reached a near plateau, suggesting we are nearing the limit of cytoreduction. It is hypothesized that this may be due to "subset effect," and that drugs administered according to responses predicted for particular subgroups within the population being treated could overcome what appears to be a limit of cytoreduction. However, the clinical trial process, as currently structured, prevents efficient discovery and validation of predictive markers of treatment response. An alternative process is proposed, based on preoperative therapy and high-throughput multiplexing of markers to provide a built-in, unbiased discovery and validation process for predictive markers. Semin Oncol 28:305-309.
journal_name
Semin Oncoljournal_title
Seminars in oncologyauthors
Paik Sdoi
10.1016/s0093-7754(01)90123-xsubject
Has Abstractpub_date
2001-06-01 00:00:00pages
305-9issue
3eissn
0093-7754issn
1532-8708pii
S009377540100118Xjournal_volume
28pub_type
杂志文章abstract：:Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-g...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2006.12.004
更新日期：2007-04-01 00:00:00
abstract：:Recurrent and second primary tumors arising within a previously radiated head and neck volume represent a difficult clinical scenario to manage. For patients who have resectable disease, surgery is the standard treatment. Chemotherapy is the standard for patients with unresectable or metastatic disease but offers no c...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2008.03.010
更新日期：2008-06-01 00:00:00
abstract：:Over the last 40 years the National Cancer Institute (NCI) has created a vibrant public-private partnership for the implementation of NCI-sponsored cooperative group (Network) clinical trials throughout the United States and Canada. Over these four decades, the cancer clinical trials process has become more complex mo...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2015.07.011
更新日期：2015-10-01 00:00:00
abstract：:This phase I/II study was done to evaluate the safety and feasibility of two schedules of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered by 1-hour infusion in the outpatient setting. Fifty-six patients with advanced, refractory malignancies received one of two paclitaxel schedules by rand...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：1994-10-01 00:00:00
abstract：:We report an open, three-armed, multicenter study being carried out to assess the optimum treatment for acute and delayed emesis and nausea in patients undergoing highly emetogenic chemotherapy. Eighty-seven patients were randomized to receive tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), tropisetron p...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：
更新日期：1994-10-01 00:00:00
abstract：:The application of molecular and genetic techniques to the study of body weight regulation have produced exciting new insights into the physiological systems governing energy expenditure, appetite, and metabolic signaling. A number of new peptides have been identified that play important roles in these regulatory syst...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1998-04-01 00:00:00
abstract：:Pancreatic cancer is the eighth most common cancer in Europe, accounting for 4.1% of cancer deaths in men and 4.8% in women. Standardized pancreatoduodenectomy and left pancreatectomy are the gold standard for routine surgical treatment of pancreatic cancer. Total pancreatectomy should be reserved for positive pancrea...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2002.37379
更新日期：2002-12-01 00:00:00
abstract：:Locoregionally advanced unresectable non-small cell lung cancer is defined by bulky primary site disease and/or regionally advanced lymphadenopathy involving the contralateral mediastinum and/or supraclavicular lymph nodes. These tumors are not amenable to curative-intent surgical resection but can be approached with ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1999-10-01 00:00:00
abstract：:In this study, it has been shown that in 21 patients with AML the dCyd kinase and dCyd deaminase activities correspond closely to the clinical response to ara-C remission induction therapy. Patients with primary disease were treated with a conventional-dose ara-C regimen whereas nonresponders and relapsed patients fol...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1987-06-01 00:00:00
abstract：:This randomized, multinational, multicenter study was designed to determine the response rate of gemcitabine monotherapy and cisplatin/etoposide combination therapy in chemotherapy-naive patients with advanced, recurrent, and/or metastatic non-small cell lung cancer (stage IIIA [if inoperable], IIIB, or IV). One group...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：
更新日期：1997-06-01 00:00:00
abstract：:Skin findings can serve as a clue to internal disease. In this article, cutaneous manifestations of underlying lung malignancy are reviewed. Paraneoplastic dermatoses are rare, but when recognized early, can lead to early diagnosis of an underlying neoplasm. Malignancy-associated dermatoses comprise a broad group of h...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2016.02.025
更新日期：2016-06-01 00:00:00
abstract：:Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,随机对照试验,评审
doi：10.1053/sonc.2003.50024
更新日期：2003-02-01 00:00:00
abstract：:Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1995-08-01 00:00:00
abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2004.10.004
更新日期：2004-12-01 00:00:00
abstract：:Pancreatic cancer is one of the most lethal neoplasms. Incidence in the United States has remained fairly stable over the past 25 years, with about 25,000 cases annually. Almost 100% of cases are fatal. Incidence in the developed world parallels that in the United States. Incidence in undeveloped nations is lower but ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1996-04-01 00:00:00
abstract：:The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metast...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2002.34116
更新日期：2002-08-01 00:00:00
abstract：:We studied the efficacy of endoscopic variceal ligation (EVL) in 16 patients with tumor thrombus of the portal vein trunk (Vp3) associated with hepatocellular carcinoma. The average (+/-SD) number of O rings used was 9.0 +/- 5.0 for the esophageal varices (n = 7) and 16.4 +/- 4.5 for the esophagogastric varices (n = 9...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1997-04-01 00:00:00
abstract：:A primary goal of current clinical cancer research is the identification of prognostic tumor subtypes. It is increasingly clear that tumor growth depends on both internal tumor factors, and factors that are external to the tumor, such as microenvironment. We recently showed that parameter values alone are less importa...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：10.1053/j.seminoncol.2015.05.004
更新日期：2015-08-01 00:00:00
abstract：:Patients with successfully treated upper aerodigestive tract (UADT) tumors commonly develop second primary tumors (SPTs). These tumors occur more often than chance would predict, arise in both the upper or lower aerodigestive tracts, are frequently preceded by leukoplakia, and are a major cause of treatment-related fa...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1016/s0093-7754(01)90048-x
更新日期：2001-02-01 00:00:00
abstract：:Over the past 5 years there has been a renewed interest in the use of monoclonal antibodies and immunoconjugates in the treatment of nonhematologic malignancies. This enthusiasm has stemmed from advances in recombinant technology allowing for the production of chimeric and humanized antibodies, from Food and Drug Admi...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：2000-12-01 00:00:00
abstract：:Maintenance therapy using rituximab is currently under consideration as a means of prolonging remission in patients with indolent non-Hodgkin's lymphoma. A phase II trial using rituximab as first-line therapy followed by maintenance treatment was carried out in patients with previously untreated indolent non-Hodgkin's...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：2004-02-01 00:00:00
abstract：:There are several treatment options for patients with metastatic colorectal cancer (mCRC), including those with disease that has progressed after treatment with chemotherapy. Bevacizumab-containing regimens show good efficacy in patients with previously treated disease. Compared with infused 5-fluorouracil, leucovorin...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2006.08.003
更新日期：2006-10-01 00:00:00
abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel-based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubic...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章
doi：
更新日期：1995-08-01 00:00:00
abstract：:Tamoxifen has been demonstrated to be hepatocarcinogenic in some but not all strains of the laboratory rat and is not a carcinogen in the mouse. To resolve the question of whether tamoxifen is genotoxic in humans, many laboratories have studied its interspecies metabolism and its propensity to form DNA adducts. This r...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1997-02-01 00:00:00
abstract：:The current resurgence in the use of nomograms as diagnostic and prognostic tools has legitimate roots in their effectiveness in facilitating communication between the doctor and patient. By returning to a more classical approach to nomography, graphical insights can further enlighten the patient beyond what can be ac...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：10.1053/j.seminoncol.2009.12.003
更新日期：2010-02-01 00:00:00
abstract：:MicroRNAs (miRNAs) are aiding our understanding of cancer biology, and are now coming close to therapeutic use as well. Here, we focus specifically on the interaction between miRNAs and genomic instability. MiRNA regulation is essential to many cellular processes, and escape from this regulatory network seems to be a ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2011.08.003
更新日期：2011-12-01 00:00:00
abstract：:Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or surviva...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,随机对照试验,评审
doi：
更新日期：1990-12-01 00:00:00
abstract：:The evaluation of the activity of new drugs against small cell lung cancer (SCLC) is discussed and the results with gemcitabine are presented. Gemcitabine has activity against untreated SCLC. Preliminary results from an ongoing study also indicate activity in so-called resistant SCLC. ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1998-08-01 00:00:00
abstract：:Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2002.31680
更新日期：2002-04-01 00:00:00
abstract：:Three hematopoietic growth factors, erythropoietin, GM-CSF, and G-CSF, have all been evaluated in the context of HIV infection. Recombinant human Epo is currently licensed for therapy of anemia related to zidovudine and is well tolerated in this patient population. Although myelosuppression can clearly be overcome usi...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,评审
doi：
更新日期：1992-08-01 00:00:00
